Heyman Richard A.
Known title: DirectorCIK: 0001584759
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Enliven's ENABLE-2 Trial Design Sparks New Questions. Enliven Therapeutics has clarified the design of its ENABLE-2 Phase 3 trial for relcobatinib in chronic myeloid leukemia, following questions raised by the trial’s structure. The company also confirmed FDA alignment on the study, while a separate patent dispute involving Halozyme and Merck has kept the leukemia treatment landscape in focus. These developments highlight the regulatory and strategic challenges Enliven faces as it moves toward clinical milestones.
Transaction History
| ORIC | ▲ Buy | Option Exercise | 3,500 | $6K | 7/24/2026 | View on chart |
| ORIC | ▼ Sell | Open Market | 7,000 | $84K | 7/24/2026 | View on chart |
| ORIC | ▼ Sell | Open Market | 6,100 | $73K | 7/24/2026 | View on chart |
| ORIC | ▼ Sell | Open Market | 300 | $4K | 7/6/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 1,230 | $32K | 2/17/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 512 | $14K | 1/20/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 718 | $19K | 1/20/2026 | View on chart |
| ORIC | ▼ Sell | Open Market | 3,500 | $42K | 1/16/2026 | View on chart |
| ORIC | ▼ Sell | Open Market | 3,200 | $38K | 1/16/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 4,285 | $107K | 1/9/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 1,620 | $41K | 1/8/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 8,015 | $201K | 1/8/2026 | View on chart |
| ORIC | ▲ Buy | Option Exercise | 31,353 | $50K | 10/3/2025 | View on chart |
| ORIC | ▲ Buy | Option Exercise | 1,447 | $5K | 10/3/2025 | View on chart |
| ELVN | ▼ Sell | Open Market | 817 | $25K | 10/18/2024 | View on chart |
| ELVN | ▼ Sell | Open Market | 753 | $23K | 10/18/2024 | View on chart |
| ELVN | ▼ Sell | Open Market | 1,270 | $35K | 10/15/2024 | View on chart |
| ELVN | ▼ Sell | Open Market | 2,825 | $78K | 10/4/2024 | View on chart |
| ELVN | ▼ Sell | Open Market | 518 | $14K | 10/1/2024 | View on chart |
| ELVN | ▼ Sell | Open Market | 1,270 | $28K | 9/16/2024 | View on chart |
| ELVN | ▼ Sell | Open Market | 650 | $15K | 8/15/2024 | View on chart |
| ELVN | ▼ Sell | Open Market | 620 | $15K | 8/15/2024 | View on chart |
| ELVN | ▼ Sell | Open Market | 649 | $18K | 7/31/2024 | View on chart |
| ELVN | ▼ Sell | Open Market | 1,702 | $47K | 7/31/2024 | View on chart |
| ELVN | ▼ Sell | Open Market | 1,270 | $31K | 7/15/2024 | View on chart |
| ELVN | ▼ Sell | Open Market | 1,270 | $27K | 6/17/2024 | View on chart |
| ELVN | ▼ Sell | Open Market | 1,270 | $30K | 5/16/2024 | View on chart |
| ELVN | ▼ Sell | Open Market | 1,190 | $24K | 4/15/2024 | View on chart |
| ELVN | ▼ Sell | Open Market | 80 | $2K | 4/15/2024 | View on chart |
| ELVN | ▼ Sell | Open Market | 5,045 | $126K | 4/11/2024 | View on chart |
| ELVN | ▼ Sell | Open Market | 649 | $16K | 4/11/2024 | View on chart |
| ELVN | ▼ Sell | Open Market | 1,270 | $18K | 3/19/2024 | View on chart |
| ELVN | ▼ Sell | Open Market | 1,270 | $22K | 2/15/2024 | View on chart |
| ELVN | ▼ Sell | Open Market | 1,270 | $21K | 1/30/2024 | View on chart |
| ELVN | ▼ Sell | Open Market | 168 | $2K | 12/22/2023 | View on chart |
| ELVN | ▼ Sell | Open Market | 35 | $455 | 12/22/2023 | View on chart |
| ELVN | ▼ Sell | Open Market | 7 | $91 | 12/21/2023 | View on chart |
| ELVN | ▼ Sell | Open Market | 6 | $78 | 12/21/2023 | View on chart |
| ELVN | ▼ Sell | Open Market | 2,110 | $27K | 12/20/2023 | View on chart |
| ELVN | ▼ Sell | Open Market | 1,915 | $25K | 12/20/2023 | View on chart |
| ELVN | ▼ Sell | Open Market | 255 | $3K | 12/19/2023 | View on chart |
| ELVN | ▲ Buy | Grant | 149,820 | — | 2/23/2023 | View on chart |
| ELVN | ▲ Buy | Grant | 37,407 | — | 2/23/2023 | View on chart |
| ELVN | ▲ Buy | Grant | 31,172 | — | 2/23/2023 | View on chart |
| ORIC | ▼ Sell | Open Market | 682 | $17K | 9/15/2021 | View on chart |
| ORIC | ▼ Sell | Open Market | 706 | $18K | 9/14/2021 | View on chart |
| ORIC | ▼ Sell | Open Market | 601 | $15K | 9/13/2021 | View on chart |
| ORIC | ▼ Sell | Open Market | 479 | $12K | 9/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
JP Morgan Upgrades ORIC, Raises Target to $26
JP Morgan has upgraded ORIC to Overweight and lifted its price target to $26, reflecting confidence in the company’s pipeline. A recent Yahoo article questions whether ORIC’s off‑balance‑sheet funding for project ORIC‑259 changes its R&D risk profile. These developments add new context to the stock’s current technical position near its 200‑day SMA and a support level of $8.69.
JP Morgan Upgrades ORIC, Raises Target to $26. JP Morgan has upgraded ORIC to Overweight and lifted its price target to $26, reflecting confidence in the company’s pipeline. A recent Yahoo article questions whether ORIC’s off‑balance‑sheet funding for project ORIC‑259 changes its R&D risk profile. These developments add new context to the stock’s current technical position near its 200‑day SMA and a support level of $8.69.